<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844142</url>
  </required_header>
  <id_info>
    <org_study_id>M01</org_study_id>
    <secondary_id>Enbrel-Sulfa-Early-AS</secondary_id>
    <nct_id>NCT00844142</nct_id>
  </id_info>
  <brief_title>Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)</brief_title>
  <official_title>Randomized Controlled 12 Months Trial With Etanercept (Enbrel ®) vs. Sulfasalazine in Early Axial Spondyloarthritis With Focus on Improvement of Acute Inflammatory Lesions as Detected by MRI. Amendment 4: 1-Year Extension of Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy - To assess efficacy of etanercept versus sulfasalazine when added to NSAIDs in&#xD;
      patients with moderate to severe active early axial spondyloarthritis duration of ongoing&#xD;
      axial symptoms of less than 5 years. Primary outcome is change of active inflammatory lesions&#xD;
      in sacroiliac joints and spine as detected by MRI at 12 months. Secondary outcome parameters&#xD;
      are clinical and laboratory efficacy parameters and MRI changes at 6 months and 2 years.&#xD;
      Comparisons will be made within the two treatment arms and compared to baseline. At the 1&#xD;
      year extension phase comparisons will be also made between year 1 and year 2. At the end of&#xD;
      the extended study a pelvic x-ray is planned.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled study with two treatment arms (Phase II), 1 year open extension&#xD;
&#xD;
      Efficacy - To assess efficacy of etanercept vs. sulfasalazine when added to NSAIDs in&#xD;
      patients with moderate to severe active early axial spondyloarthritis duration of ongoing&#xD;
      axial symptoms of less than 5 years. Primary outcome is change of active inflammatory lesions&#xD;
      in sacroiliac joints and spine as detected by MRI at 12 months. Secondary outcome parameters&#xD;
      are clinical and laboratory efficacy parameters and MRI changes at 6 months and 2 years.&#xD;
      Comparisons will be made within the two treatment arms and compared to baseline. At the 1&#xD;
      year extension phase comparisons will be also made between year 1 and year 2. At the end of&#xD;
      the extended study a pelvic x-ray is planned. For etanercept group: To assess whether&#xD;
      etanercept will show sustained long term response over 1 more year. To assess whether&#xD;
      etanercept will slow or stop progression as shown by MRI.For sulfasalazine group: to assess&#xD;
      whether etanercept will show long term response over 1 year. To assess whether etanercept&#xD;
      will slow or stop progression as shown by MRI. For all patients who are in remission the&#xD;
      duration of remission will be assessed for a maximum of one year. In case of a flare of the&#xD;
      disease these patients will be (re-) treated with etanercept and efficacy will be assessed.&#xD;
      Safety - To study the long-term safety of etanercept in patients with moderate to severe&#xD;
      active early axial spondyloarthritis compared to patients treated with sulfasalazine over a&#xD;
      period of one year.&#xD;
&#xD;
      Patients will be treated for 1 year either with etanercept 2x25mg per week subcutaneously or&#xD;
      with sulfasalazine 2g/ day given orally. Following screening and baseline evaluations,&#xD;
      patients will be assessed at week 2, 4, 6, 8, 10, 12, 24, 36 and 48. Efficacy and safety&#xD;
      measurements will be recorded throughout the entire study. The study will be followed by a 60&#xD;
      weeks follow-up phase after week 48 (end of treatment phase). In case of flare they will be&#xD;
      (re-)treated with etanercept for further 60 weeks (until week 108). All patients from the&#xD;
      former etanercept group who are not in remission will continue to be treated with etanercept&#xD;
      for 60 weeks (weeks 60, 72, 84, 96, 108). All patients from the former sulfasalazine group&#xD;
      who are not in remission will be switched to etanercept for 60 weeks (at weeks 50, 54, 60,&#xD;
      72, 84, 96, 108).&#xD;
&#xD;
      Treatment arms:Arm 1: 40 patients receive etanercept 2x25 mg weekly subcutaneous injectionArm&#xD;
      2: 40 patients receive sulfasalazine up to 2 g/day (up to 3 g/ per day)&#xD;
&#xD;
      Duration of the study:12 months. For patients in remission a 12 months follow up period will&#xD;
      be enclosed. Treatment will be continued for patients in case of flare or in patients who did&#xD;
      not achieve remission for 60 weeks. The study is planned start at September 2005. Patients&#xD;
      will be recruited over a 12 months period. Altogether the duration of the study is up to 51&#xD;
      months. All patients who are willing to participate in the extension will be treated for&#xD;
      another 60 weeks.&#xD;
&#xD;
      Patient Population:Only active axial SpA patients with a disease duration (measured from time&#xD;
      of ongoing spinal symptoms) of less than 5 years will be included. This implies that patients&#xD;
      with both radiological evidence of sacroiliitis (fulfilling the modified New York criteria&#xD;
      for AS) and without radiological evidence of sacroiliitis (see inclusion criteria) will be&#xD;
      included.&#xD;
&#xD;
      Efficacy Variables:Primary endpoint:· Reduction of active inflammatory lesions in MRI at 12&#xD;
      monthsSecondary endpoints:&#xD;
&#xD;
        -  ASAS 20%, 40%, 70% response, ASAS criteria for partial remission· BASDAI 20%, 50%, 70%&#xD;
           improvement · BASFI · Mobility examinations: BASMI, Chest Wall Expansion· disease&#xD;
           controlling antirheumatic therapy criteria (DC-ART20) (5 out of 6)*· CRP, ESR· Quality&#xD;
           of Life: SF-36· Numeric Rating Scale (NRS) - physicians global, patients global, general&#xD;
           pain, nocturnal pain · Enthesitis index (Maastricht scale)· swollen joint count· EQ-5D·&#xD;
           Socio-economic questionnaire· Chronic changes in MRI at 6, 12 months and 108 weeks·&#xD;
           Reduction of active inflammatory lesions in MRI at 6 months and chronic lesions at 6 and&#xD;
           12 months and 108 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: Reduction of active inflammatory lesions in MRI at 12 months.</measure>
    <time_frame>108 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome: ASAS 20%, 40%, 70% response, ASAS criteria for partial remission· BASDAI 20%, 50%, 70% improvement · BASFI ·</measure>
    <time_frame>108 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Moderate to Severe Active Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>etanercept 25mg twice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfasalazine 2000- 3000mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept 25mg</intervention_name>
    <description>patients will receive etanercept 25mg twice weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfasalazine</intervention_name>
    <description>in this arm patients will receive sulfasalazine 2000- 3000mg per os daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 - 50 years of age who have moderate to severe active axial&#xD;
             spondyloarthritis.&#xD;
&#xD;
          -  Diagnosis made by :Chronic low back pain (duration &gt; 3 months, onset &lt; 45 years of&#xD;
             age)plus 3 out of the 6 following criteria if imaging is positive or 4 out of the&#xD;
             following 6 criteria if imaging is negative ·&#xD;
&#xD;
          -  Inflammatory back pain:&#xD;
&#xD;
               -  Good or very good response to NSAIDs&#xD;
&#xD;
               -  One or more of the following extraspinal manifestations: uveitis, peripheral&#xD;
                  arthritis, enthesitis, HLA-B27 positive&#xD;
&#xD;
               -  Positive imaging: MRI showing acute inflammatory lesions in spine or SIJ (in the&#xD;
                  past) or bilateral sacroiliitis grade 2-4 or unilateral sacroiliitis grade 3-4 in&#xD;
                  x-ray not older than 12 months&#xD;
&#xD;
               -  Positive family history for SpA&#xD;
&#xD;
               -  MRI at screening showing acute inflammatory lesions in SIJ or spine&#xD;
&#xD;
          -  Active disease is defined as:&#xD;
&#xD;
               -  a BASDAI score of &gt;=4&#xD;
&#xD;
               -  back pain score (BASDAI question 2) of &gt;= 4 despite concurrent NSAID therapy, or&#xD;
                  intolerance to NSAIDs.&#xD;
&#xD;
          -  Other inclusion criteria include, if on prednisone:&#xD;
&#xD;
               -  &lt;7.5 mg per day&#xD;
&#xD;
               -  stable for 4 weeks prior to baseline&#xD;
&#xD;
          -  Women of child bearing potential must have a negative pregnancy test at study baseline&#xD;
             and use an adequate, effective method of contraception for a duration of 6 months&#xD;
             after stop of etanercept therapy. Sexual active men must use an accepted method of&#xD;
             contraception for a duration of 6 months after stop of etanercept therapy.&#xD;
&#xD;
          -  Reading a normal chest/lung x-ray which should have been performed within the last 12&#xD;
             weeks before inclusion&#xD;
&#xD;
          -  Able to self-administer injectable drug supplies or have a caregiver who will do so.&#xD;
&#xD;
          -  Able to store injectable test article at 2° to 8° C.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease duration of longer than 5 years&#xD;
&#xD;
          -  History of active tuberculosis (TB), histoplasmosis or listeriosis.&#xD;
&#xD;
          -  History of positive HIV status, known hepatitis B or C&#xD;
&#xD;
          -  History of malignancy other than carcinoma in situ of the cervix or adequately treated&#xD;
             non-metastatic squamous or basal cell skin carcinoma.&#xD;
&#xD;
          -  Antibiotic treatment within 3 weeks prior to screening.&#xD;
&#xD;
          -  Previous treatment with TNF-alpha blockers&#xD;
&#xD;
          -  Treatment with sulasalazine in the last 6 months before participation in the clinical&#xD;
             trial&#xD;
&#xD;
          -  severe internal medical diseases such as severe cardiac, hepatic, gastrointestinal,&#xD;
             neurological, psychiatric diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Sieper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite, Campus Benjamin-Franklin, Rheumatology, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joachim Sieper, MD</last_name>
    <phone>0049-30-8445</phone>
    <phone_ext>4535</phone_ext>
    <email>joachim.sieper@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>In-Ho Song, MD</last_name>
    <phone>0049-30-8445</phone>
    <phone_ext>4795</phone_ext>
    <email>in-ho.song@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Campus Mitte, Rheumatology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd-Ruediger Burmester, MD</last_name>
      <phone>0049-30-450513</phone>
      <phone_ext>025</phone_ext>
      <email>gerd.burmester@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Mielke</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mielke, MD</last_name>
      <phone>0049-30-994</phone>
      <phone_ext>21 22</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Zinke</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Zinke, MD</last_name>
      <phone>0049-30-98695</phone>
      <phone_ext>231</phone_ext>
      <email>dr.silke.zinke@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Krause, MD</last_name>
      <phone>0049-30-94792</phone>
      <phone_ext>380</phone_ext>
      <email>a.krause@immanuel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Waldkrankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Prothmann, MD</last_name>
      <phone>0049-30-3702-</phone>
      <phone_ext>1302</phone_ext>
      <email>u.prothmann@waldkrankenhaus.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schlossparkklinik, Rheumatology</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rieke Alten, MD</last_name>
      <phone>0049-303264-</phone>
      <phone_ext>1333</phone_ext>
      <email>rieke.alten@schlosspark-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Immanuel Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>14109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Krause, MD</last_name>
      <phone>0049-30-80505-</phone>
      <phone_ext>293</phone_ext>
      <email>a.krause@immanuel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Klopsch</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thilo Klopsch, MD</last_name>
      <phone>0049-395- 775</phone>
      <phone_ext>43 24</phone_ext>
      <email>dr.thilo.klopsch@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Bohl-Bühler</name>
      <address>
        <city>Potsdam</city>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bohl-Bühler, MD</last_name>
      <phone>0049-331- 647352</phone>
      <phone_ext>1</phone_ext>
      <email>info@Rheumahaus.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Joachim Sieper</name_title>
    <organization>Charité Rheumatology Campus Benjamin-Franklin</organization>
  </responsible_party>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>axial spondyloarthritis</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>etanercept</keyword>
  <keyword>sulfasalazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

